Welcome to Kenya Association of Pharmaceutical Industry


  Contact Us : info@kapikenya.org I Member Login

All Posts Tagged: KAPI

KAPI WEEKLY BRIEF: 15TH – 19TH FEBRUARY 2021

19th February 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • Novavax committed additional COVID-19 vaccine doses to COVAX for distribution to low and middle income countries bringing the total tally to 1.1B doses. (Endpoint News)
  • The USA plans to contribute $4 billion to COVAX in efforts to support vaccination in low income countries but has plans to control shipping of locally manufactured vaccines until the nation’s demands are met. (Bloomberg)
  • Pfizer Inc. plans to roll out a clinical trial for a booster to its vaccine shot in South Africa in response to the spreading more contagious variant. (Reuters). This follows laboratory studies that showed the S. African variant could reduce antibody protection from the Pfizer/BioNTech vaccine (Reuters)
  • Two Canadian researchers have urge for delay in administration of the second shot of the Pfizer/BioNTech vaccine which should be administered three to four weeks after the first one in efforts to extend supply to more people. (BioSpace)
  • Pfizer plans to roll out clinical trials of its vaccine in pregnant women in efforts to get data for improved care and protection for this sub-population in response to COVID-19. (NBC News)
  • The European Union launched the “HERA Incubator” as a blueprint for long-term health emergencies and a way to stop COVID-19 mutations. The incubator is set to receive €30 million from Horizon 2020. (Open Access Government)
  • The US National Institute for Health has reported that a new study, IMPAACT 2032, will analyze remdesivir in pregnant women to whom it has been prescribed for management of COVID-19 (Clinical Trials Arena)
  • WHO seeks $1.96 billion for the 2021 Strategic Plan for COVID-19 response following last year’s initial plan that outlined the path that countries should take to suppress transmission of the new coronavirus. (UN)
  • Africa is getting ready to roll out COVID-19 vaccines as reported by WHO African Regional representative Dr Moeti (WHO Africa)
  • MSF calls on wealthy nations & biopharmaceutical companies for immediate and equitable distribution of affordable and the right COVID-19 vaccines to Southern African countries. (MSF)
  • A new study looks at the probable benefit of probiotics in the management of COVID-19 given the emergence of new variants & broad spectrum of clinical disease witnessed with COVID-19. (News Medical)
  • Johnson & Johnson filed for approval of its vaccine in EU with decision probable by the middle of March according to drug regulators (Medical Xpress)
  • A research team have developed a machine learning solution aimed at identifying probable treatments for COVID-19 from those already in the market based on the disease profile and aging. (Health Europa)
  • The WHO approved AstraZeneca COVID-19 vaccine for emergency use (Wall Street Journal)
  • World Trade Organization (WTO) appoints Ngozi Okonjo Iweala as the Organizations 7th Director General (WTO)

Thank You!!!

Read More

KAPI WEEKLY BRIEF: 8TH – 12TH FEBRUARY 2021

12th February 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • A preliminary study in South Africa by University of Oxford and University of Witwatersrand have indicated inability of AstraZeneca/Oxford Vaccine to protect against mild and moderate forms of the new variant of the disease prevalent in South Africa. (The Wall Street Journal, Financial Times). On the backdrop of this, AstraZeneca and Oxford University have ventured into developing a new and improved vaccine with efficacy against the new COVID-19 variant in South Africa (Telegraph). The South African government now plans to give health workers the J&J vaccine instead (ABC News). This emerging evidence poses a challenge to other African countries on whether to use the AstraZeneca/Oxford vaccine as well (Financial Times).
  • The WHO have advised use of AstraZeneca/Oxford vaccine on all adults above 18years of age (Financial Times | UN News).
  • In efforts to boost EU COVID-19 Vaccine supplies, BioNTech reported having started production in their new facility in Germany (Medical Xpress)
  • Single dose of Pfizer vaccine shows signs of success in the UK which may make it feasible to extend gap between doses in a vaccination schedule (Financial Times)
  • Calling for an end to vaccine nationalism UNICEF Executive Director and WHO Director General urged governments to promote equitable access arguing that in this pandemic we have an option to win together or lose together. (WHO)
  • AstraZeneca plans to double up on their vaccine production to cover for shortfalls in supply that were witnessed at the start of the year. This was highlighted in the review of financial position for the previous year. (The Wall Street Journal)
  • Generic inhaled corticosteroid budesonide shows promise in treatment of COVID-19 in a small scale clinical trial (Pharma Phorum | Reuters)
  • There is a rising mortality as Africa marks one year since outbreak of COVID-19 on the backdrop of a surge in variants. (WHO African Region)
  • Dermapharm aims to start producing Pfizer vaccines at a second site in efforts to aid the drug maker meet its target of 2 billion doses by the end of the year. (Reuters)
  • Eli Lilly COVID-19 antibody combination gets FDA emergency authorization (Bloomberg)
  • Experts state that COVID-19 unlikely to have come from a lab following preliminary investigations (UN News)
  • Sinovac reports that their COVID-19 vaccine showed positive results in preventing hospitalization and death from two studies conducted in Brazil and Turkey (Reuters)
  • Pfizer vaccine effective against UK and South Africa variants of COVID-19 ( AA Com)
  • Moderna vaccine effective against new variants of the virus (News Medical Life Sciences)

Thank You!!!

Read More

KAPI WEEKLY BRIEF: 1ST – 5TH FEBRUARY 2021

5th February 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • COVAX Publishes first interim distribution forecast for COVID-19 Vaccines aimed at providing governments and health systems with the information they need to plan their national vaccination programmes. (GAVI| COVAX| Reuters |COVAX Supply Forecast)
  • AstraZeneca and Oxford University expect to have new generation vaccine against COVID-19 variants by autumn this year. (Reuters)
  • The African Union urges for equitable vaccine access and debt relief for member countries. (CGTN)
  • Mike Bloomberg and Dr. Tedros Adhanom call for global focus on Non Communicable Diseases (NCDs) to save lives from COVID-19. This came after confirmation of Bloomberg as the WHO Global Ambassador for NCDs and Injuries for the third term.(Mirage News)
  • The World Cancer Declaration: time to consolidate wins and work towards 2025. (Lancet Oncology)
  • The biopharmaceutical industry supports the establishment of African Medicines Agency (AMA) and calls on governments to ratify the AMA Treaty towards a unified continental regulatory framework. (IFPMA)
  • GSK and CureVac to start working on a next generation vaccine targeting emerging variants of the coronavirus with likelihood of being ready next year. (PharmaPhorum)
  • A new trial testing whether giving people two different COVID vaccines as first and second doses can give effective protection as using the same formulation has started. (CITYA.M)
  • A study shows that the Pfizer vaccine single shot is 90% effective after 21 days. (Medical Express)
  • Ebonyi State, South East Nigeria launched a pharmaceutical manufacturing park “Pharmacity” aimed at being the hub of quality medicine production in the whole of West Africa. (Pharma News)
  • Johnson & Johnson applies to the US FDA for Emergency Use Authorization for their vaccine which was reported to have a 66% efficacy in international clinical trials (The Wall Street Journal)
  • Africa expects to start receiving millions of vaccine doses from COVAX in February as reported by the WHO Africa Regional Office Director. (WHO |CGTN)

Thank You!!!

Read More

KAPI Leadership Pays a Courtesy visit to the PS, Ministry of Health

On Tuesday 26th January 2021 the Kenya Association of Pharmaceutical Industry (KAPI) executive board led by the Chairperson, Willy Soriney paid a courtesy visit to the Principal Secretary, Ministry of Health Madam Susan Mochache. This was part of the associations’ stakeholder engagement mechanisms aimed at fostering collaborative spirit for the advancement of the health agenda for the Kenyan people.

KAPI is a membership based association representing research and development based biopharmaceutical companies in the country and plays a critical in role in promoting efficiencies in the pharmaceutical industry through policy advocacy, thought leadership, market intelligence and promotion of ethical business practices in the sector. These are geared towards ensuring Kenyans have access to high quality, safe and efficacious health products and technologies.

The discussions with the PS centred on prevailing concerns in the sector ranging from COVID-19 vaccines, taxation and pricing of medicines, local manufacturing of medicines and regulatory landscape. The association through its membership committed to collaborate with and support the ministry in its COVID-19 vaccine procurement and deployment strategy to ensure we served our social and moral obligation to our people.

Focusing on the cost of medicines which were noted to be higher than other countries in the region, it was noted that as a country we have unfavourable tax regimes that work against our common commitment to lower prices of medicines. It was noted that the Ministry of Health had taken a lead role in streamlining these with the establishment of a special committee spearheading the discussions to develop a plan that will ensure Kenyans can access safe, effective and quality healthcare products and technologies affordably as espoused in the UHC decree.

COVID-19 exposed shortfalls in the pharmaceutical industry especially with regard to reliance on imports of health products. This has brought attention and focus on promotion of local manufacturing as a strategy to secure supplies for the country. Acknowledging the need to support local manufacturing, KAPI leadership pointed out on the need for a strategic approach driven by incentives for local production and a favourable regulatory environment with stability & predictability. These are key drivers to investment and without investment it’s impossible to have a favourable local pharmaceutical industry.

The ministry commended such engagements acknowledging the critical role that the private sector has in supporting governments in realizing their agenda. “National development is a collaborative and joint agenda and the proactive approach by the association to drive a futuristic and sustainable agenda in the industry with the government is an indication of the ability to steer clear of the current hurdles and emerge victorious” stated the PS.

Read More